Abstract
Immunoglobulin light chain (LC) proteins exhibit the greatest sequence variability of all proteins associated with amyloid disease. The hallmark event in amyloidogenesis is a change in the secondary and / /or tertiary structure of a normal, soluble protein, that fosters selfaggregation and fibril formation. The structural heterogeneity of light chain proteins has hampered understanding of the precise mechanisms involved in fibril formation. The development of effective therapeutics will be benefited by a fundamental understanding of mechanisms and structural prerequisites which govern amyloidogenesis. This review focuses on light chain (AL) amyloidosis resulting from the aggregation of κ and λ LCs. Specifically the thermodynamic and structural data of several WT and mutant amyloidogenic LCs have been carefully examined. Moreover, we discuss the importance of hydrophobic and ionic interactions on amyloidosis by comparing several available three-dimensional structures of amyloidogenic and highly homologous non-amyloidogenic proteins that can be destabilized to become amyloidogenic by site specific mutations.
Keywords: Human Amyloid Disease, non-amyloidogenic proteins, thermodynamic, amyloidogenesis
Current Drug Targets
Title: Towards Understanding the Structure-Function Relationship of Human Amyloid Disease
Volume: 5 Issue: 2
Author(s): Chris Dealwis and Jonathan Wall
Affiliation:
Keywords: Human Amyloid Disease, non-amyloidogenic proteins, thermodynamic, amyloidogenesis
Abstract: Immunoglobulin light chain (LC) proteins exhibit the greatest sequence variability of all proteins associated with amyloid disease. The hallmark event in amyloidogenesis is a change in the secondary and / /or tertiary structure of a normal, soluble protein, that fosters selfaggregation and fibril formation. The structural heterogeneity of light chain proteins has hampered understanding of the precise mechanisms involved in fibril formation. The development of effective therapeutics will be benefited by a fundamental understanding of mechanisms and structural prerequisites which govern amyloidogenesis. This review focuses on light chain (AL) amyloidosis resulting from the aggregation of κ and λ LCs. Specifically the thermodynamic and structural data of several WT and mutant amyloidogenic LCs have been carefully examined. Moreover, we discuss the importance of hydrophobic and ionic interactions on amyloidosis by comparing several available three-dimensional structures of amyloidogenic and highly homologous non-amyloidogenic proteins that can be destabilized to become amyloidogenic by site specific mutations.
Export Options
About this article
Cite this article as:
Dealwis Chris and Wall Jonathan, Towards Understanding the Structure-Function Relationship of Human Amyloid Disease, Current Drug Targets 2004; 5 (2) . https://dx.doi.org/10.2174/1389450043490550
DOI https://dx.doi.org/10.2174/1389450043490550 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Plastid Structure, Diversification and Interconversions II. Land Plants
Current Chemical Biology Restoring the Phenotype of Fragile X Syndrome: Insight from the Mouse Model
Current Molecular Medicine Antivenoms for Snakebite Envenomings
Inflammation & Allergy - Drug Targets (Discontinued) New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry The Association between Metabolic Syndrome and Serum Levels of Adiponectin and High Sensitive C Reactive Protein in Gorgan
Endocrine, Metabolic & Immune Disorders - Drug Targets Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs
Current Pharmaceutical Design PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Targeting the LKB1 Tumor Suppressor
Current Drug Targets Protein Microarrays: Valuable Tools for Ocular Diseases Research
Current Medicinal Chemistry Small RNAs Play Big Roles: MicroRNAs in Diabetic Wound Healing
Current Molecular Medicine TGF-β: Its Role in Asthma and Therapeutic Potential
Current Drug Targets The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Drugs Targeting Parasite Lysosomes
Current Pharmaceutical Design Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued)